Unisom
Unisom Price range: $ 46,00 through $ 232,00
Back to products
Uroxatral
Uroxatral Price range: $ 52,00 through $ 324,00

Urispas

Price range: $ 48,00 through $ 385,00

Urispas is an effective antispasmodic medication designed to provide targeted relief from painful symptoms of the urinary tract. It works by relaxing the smooth muscles of the bladder to reduce the frequent or urgent impulses to urinate. This medication is primarily used to manage discomfort associated with common conditions such as cystitis, prostatitis, and urethritis. Patients often rely on Urispas to alleviate symptoms like painful urination, nighttime frequency, and suprapubic pain. By directly addressing bladder spasms, Urispas helps restore comfort and improves the overall quality of life for those experiencing urinary irritation.

Active substance: Flavoxate
SKU: Urispas Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Urispas belongs to a class of therapeutic agents designated as urinary antispasmodics. It contains the active pharmaceutical ingredient flavoxate hydrochloride, which acts directly as a smooth muscle relaxant on the lower urinary tract to alleviate muscular spasms and related discomfort.

In the United States, Urispas is classified as a prescription-only medication regulated by the US Food and Drug Administration (FDA). It is indicated to provide relief for symptomatic conditions involving bladder instability and lower urinary tract irritation, requiring formal diagnosis and medical supervision by a licensed healthcare provider prior to administration.

Attribute Specification
Drug Name Urispas
Active Ingredient Flavoxate hydrochloride
Therapeutic Class Urinary antispasmodic / Smooth muscle relaxant
Dosage Form Oral tablet
Route of Administration Oral
Prescription Status Prescription (Rx only)

How the drug works

Urispas exerts its primary pharmacologic effect through direct spasmolytic action on the smooth muscle tissue of the urinary tract. The active constituent, flavoxate hydrochloride, counteracts smooth muscle contractions independently of autonomic nervous innervation. Mechanistically, flavoxate inhibits phosphodiesterase enzymes and exhibits intracellular calcium-antagonistic properties within smooth muscle cells, leading to muscle relaxation.

Additionally, Urispas displays weak local anesthetic and analgesic properties, which help decrease pain sensations originating from irritated mucosal surfaces of the bladder and urethra. Clinical studies demonstrate that flavoxate increases effective bladder capacity in patients exhibiting spastic bladder conditions, reduces detrusor muscle hypertonicity, and decreases the frequency of involuntary micturition impulses without suppressing normal voluntary voiding mechanisms.

Main uses

Urispas is FDA-approved for the symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, urinary frequency, and urge incontinence. These symptoms are frequently associated with inflammatory or infectious conditions of the lower urinary tract, including cystitis, prostatitis, urethritis, urethrocystitis, and urethrotrigonitis.

It is important to emphasize that Urispas serves solely as an antispasmodic and analgesic agent for symptom management; it does not possess intrinsic antibacterial activity. When lower urinary tract symptoms are secondary to a bacterial infection, Urispas must be co-administered with appropriate antimicrobial therapy targeted at the causative pathogen. Use of Urispas for unapproved functional bladder disorders without medical evaluation is considered off-label and requires specific physician guidance.

Dosing schedule

The standard dosage regimen for Urispas in adults and pediatric patients over 12 years of age is one 100 mg or 200 mg tablet taken orally three to four times daily. Dosing schedule adjustments depend on the severity of symptoms and individual clinical response. As symptomatic improvement occurs, a healthcare provider may adjust or taper the total daily dose.

  • Take tablets whole with a full glass of water.
  • If gastrointestinal upset occurs, administration alongside meals or milk is recommended.
  • Safety and efficacy in pediatric patients under 12 years of age have not been established.

What happens in the body

Following oral administration, flavoxate hydrochloride is rapidly absorbed from the gastrointestinal tract. The parent compound undergoes extensive and rapid biotransformation in the liver, primary conversion producing its principal active metabolite, methyl flavone carboxylic acid (MFCA).

Peak plasma concentrations of MFCA are typically attained within 1 to 2 hours after oral ingestion. Systemic bioavailability is high due to rapid metabolic conversion. Elimination occurs predominantly through the kidneys, with approximately 57% to 60% of an administered dose excreted in the urine as MFCA within 12 hours of administration. Flavoxate and its metabolites show minimal tissue accumulation under standard therapeutic dosing intervals.

Compatibility with other medicines

Concomitant administration of Urispas with other medications exhibiting anticholinergic or central nervous system (CNS) depressant properties may result in additive pharmacological effects. Patients should inform their prescriber of all current medications, including prescription drugs, over-the-counter products, and dietary supplements.

Potential drug interactions include:

  • CNS Depressants: Sedatives, tranquilizers, or opioid analgesics may enhance somnolence and dizziness when combined with flavoxate.
  • Anticholinergic Agents: Drugs with antimuscarinic actions (such as certain antihistamines, tricyclic antidepressants, or antiparkinsonian agents) may exacerbate dry mouth, constipation, and urinary retention.
  • Gastrointestinal Prokinetics: Antispasmodic effects of flavoxate may antagonize the therapeutic action of drugs intended to stimulate gastrointestinal motility.

What side effects may occur

Therapy with Urispas is generally well-tolerated, but adverse reactions can occur. Most side effects are transient and related to the mild anticholinergic and central nervous system actions of the drug.

Common adverse events include:

  • Nausea and vomiting
  • Dryness of the mouth
  • Drowsiness, vertigo, or headache
  • Nervousness or mental confusion (particularly in elderly patients)
  • Blurred vision and accommodation disturbances
  • Tachycardia or palpitations
  • Transient dysuria or skin hypersensitivity reactions (such as rash or urticaria)

Important precautions

Urispas is contraindicated in patients with known hypersensitivity to flavoxate hydrochloride or any component of the formulation. It is strictly contraindicated in patients presenting with obstructive anatomical or functional conditions of the gastrointestinal tract, including pyloric or duodenal obstruction, obstructive intestinal lesions, intestinal ileus, achalasia, or active gastrointestinal hemorrhage.

Additionally, Urispas must not be administered to individuals with obstructive uropathies of the lower urinary tract, such as severe bladder neck obstruction due to prostatic hypertrophy. Caution is advised when prescribing Urispas to patients with glaucoma or elevated intraocular pressure due to potential anticholinergic effects on ocular dynamics.

Regarding special populations:

  • Pregnancy: Urispas should be used during pregnancy only if clearly needed and explicitly prescribed by a physician.
  • Nursing Mothers: It is not definitively known whether flavoxate is excreted in human milk; caution should be exercised when administered to a nursing woman.
  • Geriatric Use: Elderly patients may exhibit increased susceptibility to central nervous system adverse effects, such as confusion, dizziness, and dry mouth.

Food and alcohol interactions

Administration of Urispas with food or milk can assist in reducing potential upper gastrointestinal discomfort, such as nausea or gastric irritation. Food does not significantly impair the overall extent of absorption of the active metabolite.

Alcohol consumption should be strictly avoided or limited during treatment with Urispas. Concomitant intake of ethanol can intensify central nervous system depression, leading to heightened drowsiness, impaired motor coordination, and reduced cognitive alertness.

If you skip a dose

If a dose of Urispas is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed tablet should be omitted, and the regular dosing schedule resumed.

Patients must never double the dose or take extra tablets to compensate for a missed administration. Exceeding prescribed dosages increases the likelihood of experiencing central nervous system and anticholinergic side effects.

Signs of improvement

Therapeutic response to Urispas is typically observed within 1 to 3 hours following oral administration, as smooth muscle relaxation occurs. Patients may observe a measurable reduction in the urgency and frequency of urination, attenuation of suprapubic or bladder pain, and relief from dysuria.

Clinical efficacy is evaluated by the stabilization of lower urinary tract function and symptom abatement. If symptoms persist without improvement after several days of treatment, or if fever, hematuria, or severe flank pain develops, immediate re-evaluation by a healthcare provider is required.

Storage and expiration

Urispas tablets should be stored at controlled room temperature between 59°F and 86°F (15°C and 30°C). Keep the container tightly closed and protect the medication from excessive moisture, heat, and direct light exposure.

Store all medications safely out of the reach and sight of children and pets. Do not use Urispas past the expiration date printed on the packaging. Unused or expired medication should be disposed of in accordance with local pharmaceutical waste disposal guidelines or drug take-back programs.

Common questions

Does Urispas treat the underlying bacterial infection causing bladder symptoms?

No, Urispas is not an antibiotic and does not possess antibacterial properties. It functions exclusively as a smooth muscle relaxant and local analgesic to relieve symptoms such as pain, frequency, and spasms. If a bacterial urinary tract infection is present, a prescribed course of anti-infective therapy must be taken concurrently with Urispas.

How does Urispas affect central nervous system tasks like driving?

Urispas may cause drowsiness, blurred vision, or vertigo in certain individuals. Consequently, patients should exercise caution when operating motor vehicles, operating machinery, or performing tasks requiring full mental alertness until their individual response to the medication has been determined.

Can Urispas be taken alongside over-the-counter pain relievers?

Generally, Urispas can be co-administered with standard non-prescription analgesics such as acetaminophen or ibuprofen if recommended by a healthcare provider. However, patients should avoid combining Urispas with over-the-counter antihistamines or sleep aids that possess anticholinergic properties without prior professional consultation.

Is Urispas suitable for individuals diagnosed with glaucoma?

Urispas must be used with extreme caution in patients with glaucoma, particularly closed-angle glaucoma. Because the drug exerts weak anticholinergic activity, it has the potential to elevate intraocular pressure. Patients with ocular conditions must consult their ophthalmologist and prescriber before initiating therapy.

What should be done if urinary urgency does not improve after several days?

If lower urinary tract symptoms fail to show improvement, or if they worsen during treatment, patients should contact their healthcare provider promptly. Persistent symptoms may indicate an unaddressed infection, anatomical obstruction, or an alternative underlying urological condition requiring diagnostic re-evaluation.

In accordance with FDA requirements.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.

Additional information
Dosage

200mg

Package

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία